For the Inventor, By the Inventor

Enter assignee name

Hong Kong, China

Insilico Medicine IP Limited

Calculating rank

USPTO Granted Patents = 40

EPO Patents = 1

Trademarks = 7

Forward Citations = 47

Loading Chart...

Loading Chart...

62 inventors (with patents filed for the assignee):

Aleksandr M Aliper (20 out of 22 patents)

Aleksandrs Zavoronkovs (16 out of 18 patents)

Feng Ren (10 out of 24 patents)

4. Daniil Polykovskiy (9 out of 9 patents)

5. Vladimir Aladinskiy (9 out of 9 patents)

6. Xiao Ding (9 out of 15 patents)

7. Aleksandrs Zavoronkovs (8 out of 9 patents)

8. Yan A Ivanenkov (7 out of 7 patents)

9. Alexander Zhebrak (5 out of 5 patents)

10. Luoheng Qin (5 out of 9 patents)

11. Maksim Kuznetsov (4 out of 4 patents)

12. Jianyu Xu (4 out of 4 patents)

13. Liena Qin (4 out of 4 patents)

14. Artur Kadurin (3 out of 3 patents)

15. Evgeny Putin (3 out of 3 patents)

Core Competencies:

Molecular Generation

Kinase Inhibitors

TLR Inhibitors

Beta-lactam Derivatives

PHD Inhibitors

Deep Generative Models

Small Molecule Inhibitors

Drug Discovery

Autoencoders

SARS-CoV-2 Inhibitors

Biological Activity

Longevity Therapeutics

40 patents: Sort by Forward Citations

1. 12760036 - Inhibitors of KIF18A and uses thereof (2026-10-13),

2. 12718908 - Graph normalizing flow for hierarchical molecular generation (2026-08-25),

3. 12570634 - Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof (2026-03-10),

4. 12462900 - Retrosynthesis systems and methods (2025-11-04),

5. 12410156 - Kinase inhibitors (2025-09-09),

6. 12380329 - Structure-based deep generative model for binding site descriptors extraction and de novo molecular generation (2025-08-05),

7. 12307379 - Subset conditioning using variational autoencoder with a learnable tensor train induced prior (2025-05-20),

8. 12293809 - Workflow for generating compounds with biological activity against a specific biological target (2025-05-06),

9. 12286443 - Bycyclic JAK inhibitors and uses thereof (2025-04-29),

10. 12282851 - Mutual information adversarial autoencoder (2025-04-21),

11. 12227493 - Methods of inhibiting kinases (2025-02-18),

12. 12209101 - Prolyl hydroxylase domain-containing protein (PHD) inhibitors and uses thereof (2025-01-28),

13. 12162862 - Beta-lactam derivatives for the treatment of diseases (2024-12-10),

14. 12103915 - TEAD inhibitors and methods of uses thereof (2024-10-01),

15. 12091406 - Lysine acetyltransferase 6A (KAT6A) inhibitors and uses thereof (2024-09-17),

Company Overview

Insilico Medicine IP Limited is a biotechnology company based in Hong Kong, specializing in the application of artificial intelligence and machine learning to drug discovery and development. The organization focuses on creating innovative solutions that enhance the efficiency of the pharmaceutical industry, particularly in the areas of aging research and age-related diseases. By leveraging advanced computational techniques, Insilico aims to accelerate the identification of potential therapeutic candidates and optimize the drug development process.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

40 Patents

#82 in Hong Kong

#787 in China

#17,081 in the World

Hong Kong, China

Insilico Medicine IP Limited

Forward Citations = 47

62 inventors:

Aleksandr M Aliper (20 out of 22 patents)

Aleksandrs Zavoronkovs (16 out of 18 patents)

Feng Ren (10 out of 24 patents)

4. Daniil Polykovskiy (9 out of 9 patents)

5. Vladimir Aladinskiy (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Insilico Medicine IP Limited. Retrieved from https://idiyas.com/company/insilico-medicine-ip

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…